Literature DB >> 9005900

Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus.

M A Mont1, A C Fairbank, M Petri, D S Hungerford.   

Abstract

A cross sectional study was performed to try to identify various demographic and radiologic risk factors for disease progression in 50 patients (79 hips) with corticosteroid associated osteonecrosis of the femoral head who had a core decompression. Thirty-one of the hips were in 18 patients who had systemic lupus erythematosus and were compared with the remaining group of 48 hips in 32 patients who were taking corticosteroids for other reasons. All patients in the study had been taking greater than 30 mg of prednisone for at least 2 weeks at least 6 months before the onset of osteonecrosis. Patients underwent a core decompression and were then observed for an average of 12 years (range, 4-18 years). Overall, 42 of the 79 hips (53%) had satisfactory outcomes. Of the 31 hips in patients with systemic lupus erythematosus, 21 (68%) were converted to a total hip replacement. In the patients without systemic lupus erythematosus taking corticosteroids, 16 of 48 hips (33%) progressed to arthroplasty. A subset of 25 hips from each group (systemic lupus erythematosus and without systemic lupus erythematosus) were matched for age, gender, prednisone dose, Ficat and Arlet Stage, and length of followup. The matched group without systemic lupus erythematosus had 44% survival (11 of 25 hips), which was not statistically different when compared with the 36% survival (9 of 25 hips) found in the systemic lupus erythematosus group. The major risk factors for disease progression were late stage of disease (Stage III) at presentation and radiographic extent of the lesion (>200 degrees), regardless of diagnosis. None of the factors that have been found to be associated with osteonecrosis in patients with systemic lupus erythematosus could be associated with disease progression. Because cause seems to be less significant than the onset and extent of the disease, the clinician should make the diagnosis of osteonecrosis as promptly as possible so that treatment can be started at the earliest possible time, when it will be most efficacious.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005900

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

1.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.

Authors:  J Calvo-Alén; G McGwin; S Toloza; M Fernández; J M Roseman; H M Bastian; E J Cepeda; E B González; B A Baethge; B J Fessler; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

Review 2.  Osteonecrosis in patients with SLE.

Authors:  Mahmoud Abu-Shakra; Dan Buskila; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

3.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

4.  Core decompression versus other joint preserving treatments for osteonecrosis of the femoral head: a meta-analysis.

Authors:  Francesco Sadile; Alessio Bernasconi; Sergio Russo; Nicola Maffulli
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

Review 5.  Do modern techniques improve core decompression outcomes for hip osteonecrosis?

Authors:  David R Marker; Thorsten M Seyler; Slif D Ulrich; Siddharth Srivastava; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2008-04-08       Impact factor: 4.176

Review 6.  Treatment of osteonecrosis in systemic lupus erythematosus: a review.

Authors:  T Andrew Ehmke; Jeffrey J Cherian; Eddie S Wu; Julio J Jauregui; Samik Banerjee; Michael A Mont
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

7.  Concentrated autologous bone marrow aspirate transplantation treatment for corticosteroid-induced osteonecrosis of the femoral head in systemic lupus erythematosus.

Authors:  Tomokazu Yoshioka; Hajime Mishima; Hiroshi Akaogi; Shinsuke Sakai; Meihua Li; Naoyuki Ochiai
Journal:  Int Orthop       Date:  2010-05-29       Impact factor: 3.075

8.  Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication.

Authors:  Paola Caramaschi; Domenico Biasi; Ilaria Dal Forno; Silvano Adami
Journal:  Autoimmune Dis       Date:  2012-08-05

9.  Stem cell implantation for osteonecrosis of the femoral head.

Authors:  Young Wook Lim; Yong Sik Kim; Jong Wook Lee; Soon Yong Kwon
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

10.  Multiple drilling combined with simvastatin versus multiple drilling alone for the treatment of avascular osteonecrosis of the femoral head: 3-year follow-up study.

Authors:  Han Yin; Zhenfeng Yuan; Dawei Wang
Journal:  BMC Musculoskelet Disord       Date:  2016-08-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.